By acquiring Mumbai-based Synergia Life Sciences, Novozymes strengthens and accelerates its position in human health and functional foods adding strong developing and manufacturing capabilities in spore probiotics and vitamin K2-7.
The vitamin K2-7 portfolio is a strong complementary enabler to support growth in Denmark-based Novozymes’ BioHealth platform. The acquisition offers a scientifically proven portfolio that strengthens Novozymes’ human health business and accelerates its functional food offerings.
Synergia Life Scienes is already a key supplier to Microbiome Labs, which was acquired by Novozymes in early 2021. The founders of Synergia will continue to be actively involved in the business.
"Novozymes’ strong presence in the functional foods and dietary supplement space makes this a strategic fit for Synergia’s innovative product portfolio," says Dilip Mehta, CEO of Synergia Life Sciences.